Abbott receives fda's breakthrough device designation to explore use of deep brain stimulation to manage severe depression

Breakthrough device designations are given by the u.s. fda to expedite the review of technologies that can improve the lives of people with life-threatening or debilitating conditions each year, 2.8 million americans will fail multiple depression therapies and be diagnosed with treatment-resistant depression (trd) with breakthrough device designation, abbott's deep brain stimulation (dbs) system could become available as a new treatment option sooner for people affected by trd abbott park, ill., july 12, 2022 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has granted breakthrough device designation to investigate the use of its deep brain stimulation (dbs) system in treatment-resistant depression (trd), a form of major depressive disorder (mdd).
ABT Ratings Summary
ABT Quant Ranking